Stockscreener 앱 받기
8.85
0.45%
-0.04
시간 외 거래:
8.84
-0.010
-0.11%
전일 마감가:
$8.89
열려 있는:
$8.93
하루 거래량:
103.78K
Relative Volume:
0.60
시가총액:
$189.19M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-1.7879
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
+5.36%
1개월 성능:
+19.43%
6개월 성능:
+24.65%
1년 성능:
-25.25%
1일 변동 폭
$8.72
$9.08
1주일 범위
$8.33
$9.17
52주 변동 폭
$4.09
$13.37
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
8.85 | 190.05M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Real time pattern detection on Enanta Pharmaceuticals Inc. stockJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
What’s the outlook for Enanta Pharmaceuticals Inc.’s sectorMarket Growth Report & Consistent Profit Trading Strategies - خودرو بانک
Visualizing Enanta Pharmaceuticals Inc. stock with heatmapsWeekly Profit Report & Detailed Earnings Play Strategies - Newser
Using data filters to optimize entry into Enanta Pharmaceuticals Inc.Trade Exit Report & Fast Exit Strategy with Risk Control - Newser
What are the future prospects of Enanta Pharmaceuticals Inc.Weekly Trading Summary & Technical Buy Zone Confirmation - خودرو بانک
How to manage a losing position in Enanta Pharmaceuticals Inc.Trade Exit Report & Comprehensive Market Scan Insights - Newser
How to build a dashboard for Enanta Pharmaceuticals Inc. stockBull Run & Entry Point Confirmation Alerts - Newser
Applying Elliott Wave Theory to Enanta Pharmaceuticals Inc.Bull Run & Daily Risk Controlled Trade Plans - Newser
Is a relief rally coming for Enanta Pharmaceuticals Inc. holdersTrade Analysis Summary & Stepwise Trade Signal Guides - Newser
What MACD and RSI say about Enanta Pharmaceuticals Inc.Gold Moves & Real-Time Price Movement Reports - Newser
Will Enanta Pharmaceuticals Inc. see short term momentumWeekly Risk Summary & Capital Efficient Trading Techniques - Newser
Using data tools to time your Enanta Pharmaceuticals Inc. exit2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - Newser
How to build a custom watchlist for Enanta Pharmaceuticals Inc.Index Update & AI Enhanced Trading Alerts - Newser
Real time social sentiment graph for Enanta Pharmaceuticals Inc.Weekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
Enanta CFO dies after taking medical leave of absence - CFO Dive
Enanta Pharmaceuticals Announces the Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr. - citybiz
Enanta Pharmaceuticals Appoints Interim Financial Officers - MSN
Tools to monitor Enanta Pharmaceuticals Inc. recovery probabilityJuly 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial a - PharmiWeb.com
Live market analysis of Enanta Pharmaceuticals Inc.Portfolio Profit Report & Weekly Stock Performance Updates - Newser
Enanta Pharmaceuticals announces passing of longtime CFO Paul Mellett - Investing.com
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Price Is Right But Growth Is Lacking After Shares Rocket 27% - simplywall.st
Enanta Pharmaceuticals: Leadership Continuity and Strategic Resilience in Biotech R&D - AInvest
Enanta Pharmaceuticals Chief Financial, Administrative Officer Dies - MarketScreener
Enanta Pharmaceuticals Announces the Passing of its Beloved and - GuruFocus
Enanta Pharmaceuticals Receives New 'Buy' Rating from WestPark Capital with $24.00 Price Target - AInvest
What recovery options are there for Enanta Pharmaceuticals Inc.Market Movement Recap & Free Low Drawdown Momentum Trade Ideas - Newser
Enanta Pharmaceuticals Announces Passing of Chief Financial and Administrative Officer Paul J. Mellett Jr. - AInvest
Two Decades of Leadership: Enanta Pharmaceuticals Mourns Loss of CFO Who Helped Cure 1M+ HCV Patients - Stock Titan
Historical volatility pattern of Enanta Pharmaceuticals Inc. visualizedJuly 2025 Sector Moves & Reliable Entry Point Alerts - Newser
Measuring Enanta Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - Newser
Published on: 2025-09-03 03:49:04 - Newser
Short interest data insights for Enanta Pharmaceuticals Inc.Insider Selling & Precise Buy Zone Tips - Newser
Can you recover from losses in Enanta Pharmaceuticals Inc.2025 Investor Takeaways & Expert Approved Trade Ideas - Newser
Is Enanta Pharmaceuticals Inc. reversing from oversold territory2025 Technical Patterns & AI Driven Price Predictions - Newser
Key resistance and support levels for Enanta Pharmaceuticals Inc.July 2025 Short Interest & Long-Term Growth Plans - Newser
Is Enanta Pharmaceuticals Inc. forming a breakout patternJuly 2025 Movers & Technical Buy Zone Confirmations - خودرو بانک
Enanta Pharma (ENTA) Receives New 'Buy' Rating from WestPark Cap - GuruFocus
Can momentum traders help lift Enanta Pharmaceuticals Inc.2025 Sector Review & Consistent Profit Trading Strategies - Newser
Enanta Pharmaceuticals: WestPark Capital initiates coverage with a Buy rating and $24 PT. - AInvest
Aug Chart Watch: Will Enanta Pharmaceuticals Inc. be affected by tariffsJuly 2025 Retail & Weekly High Return Forecasts - خودرو بانک
Can Enanta Pharmaceuticals Inc. rally from current levelsWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):